References of "Bergsten, Peter"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA six month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity
Weghuber, Daniel; Forslund, Anders; Ahlström, Hakan et al

in Pediatric Obesity (2020)

Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor-agonist could be a treatment option for adolescent obesity. Objective ... [more ▼]

Background: Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor-agonist could be a treatment option for adolescent obesity. Objective: To investigate the effect of exenatide extended-release on body-mass-index (BMI)- SDS as primary outcome, and glucose-metabolism, cardiometabolic risk factors liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. Methods: Six-months, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n=44, 10-18 years, females n=22) with BMI-SDS>2.0 or age-adapted-BMI>30 kg/m² according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended-release 2 mg (n=22) or placebo (n=22) sub-cutaneousinjections given once weekly. Oral-glucose-tolerance-tests (OGTT) were conducted at the beginning and end of the intervention. Results: Exenatide reduced (p<0.05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (- 2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm3; -989, -114), 2-hour-glucose during OGTT (-15.3 mg/dL; -27.5, -3.1), total cholesterol (11.6 mg/dL; -21.7, -1.5) and BMI (-0.83 kg/m²; -1.68, 0.01) without significant change in liver fat content (-1.36; -3.12, 0.4; p=0.06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide-treated patients. Conclusions: Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI-reduction for the patient group. [less ▲]

Detailed reference viewed: 27 (0 UL)
Full Text
Peer Reviewed
See detailSignaling in Insulin-Secreting MIN6 Pseudoislets and Monolayer Cells.
Chowdhury, Azazul; Satagopam, Venkata UL; Manukyan, Levon et al

in Journal of proteome research (2013)

Cell-cell interactions are of fundamental importance for cellular function. In islets of Langerhans, which control blood glucose levels by secreting insulin in response to the blood glucose concentration ... [more ▼]

Cell-cell interactions are of fundamental importance for cellular function. In islets of Langerhans, which control blood glucose levels by secreting insulin in response to the blood glucose concentration, the secretory response of intact islets is higher than that of insulin-producing beta-cells not arranged in the islet architecture. The objective was to define mechanisms by which cellular performance is enhanced when cells are arranged in three-dimensional space. The task was addressed by making a comprehensive analysis based on protein expression patterns generated from insulin-secreting MIN6 cells grown as islet-like clusters, so-called pseudoislets, and in monolayers. After culture, glucose-stimulated insulin secretion (GSIS) was measured from monolayers and pseudoislets. GSIS rose 6-fold in pseudoislets but only 3-fold in monolayers when the glucose concentration was increased from 2 to 20 mmol/L. Proteins from pseudoislets and monolayers were extracted and analyzed by liquid-chromatography mass spectrometry, and differentially expressed proteins were mapped onto KEGG pathways. Protein profiling identified 1576 proteins, which were common to pseudoislets and monolayers. When mapped onto KEGG pathways, 11 highly enriched pathways were identified. On the basis of differences in expression of proteins belonging to the pathways in pseudoislets and monolayers, predictions of differential pathway activation were performed. Mechanisms enhancing insulin secretory capacity of the beta-cell, when situated in the islet, include pathways regulating glucose metabolism, cell interaction, and translational regulation. [less ▲]

Detailed reference viewed: 158 (2 UL)